Northbrook, IL 60062 -- (SBWIRE) -- 11/29/2023 -- Image-Guided Radiation Therapy Market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period. Cancers, such as head and neck cancer, prostate cancer, lung cancer, and breast cancer diseases, are on the rise globally. Image-guided radiation therapy is extensively used in non-invasive cancer treatments, including radiation therapy, to treat these conditions. The growing burden of cancer is driving the demand for image-guided radiation therapy. Increasing awareness and availability of non-invasive treatments, rising demand for image-guided radiation therapy, and Increasing government initiatives to manage cancerous diseases in healthcare are a few drivers that collectively contribute to the growth of the image-guided radiation therapy market, and as healthcare technologies continue to evolve, the demand for image-guided radiation therapy is expected to rise further in the coming years. However, higher initial investment cost limits the entry of new participants and market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171554723

Browse in-depth TOC on "Image-Guided Radiation Therapy Market"

116 - Tables
41 - Figures
202 – Pages

Key Market Players:

As of 2022, prominent players in the image-guided radiation therapy market are Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Driver: Increase in non-invasive cancer treatments through radiation therapy

Non-invasive radiation therapy significantly mitigates the probability of surgical complications and diminishes the potential for adverse effects in the post-treatment phase. This augmentation distinctly contributes to the advancement and market elevation of image-guided radiation therapy, positioning it as a pivotal solution in the landscape of cancer treatment.

Increasing government initiatives for cancer management:

The augmentation of government initiatives for cancer management is driven by a confluence of factors, encompassing imperatives in public health, deliberations of economic significance, advocacy on behalf of patients, commitments on the global stage, and a unified endeavor to bolster healthcare systems and foster health equity. This amalgamation distinctly contributes to the advancement and market elevation of image-guided radiation therapy, solidifying its position as a pivotal solution within the broader spectrum of cancer treatment modalities.

Rising cancer patient population:

The upward trajectory of the cancer patient population stems from a multifaceted interplay of interconnected elements that collectively influence individual susceptibility and contribute to the overarching burden of cancer across societies. This intricate amalgamation distinctly contributes to the advancement and market elevation of image-guided radiation therapy, positioning it as an instrumental solution within the expansive domain of cancer care and treatment.

PET/ MRI-guided radiation therapy segment to register a significant growth rate over the forecast period of 2022-2028.

Based on the product, the image-guided radiation therapy market is segmented into LINAC (linear accelerator), 4D gating/ 4D RT, PET/ MRI-guided radiation therapy, CT scanning, and portal imaging. The capability of PET/MRI to furnish functional insights directs the administration of radiation doses, effectively mitigating healthy tissue exposure and subsequently alleviating the occurrence of adverse effects. This contribution significantly bolsters the market trajectory of image-guided radiation therapy, enhancing its appeal and positioning within the healthcare landscape.

PET/MRI facilitates the concurrent capture of both structural and molecular data, offering valuable support for treatment strategizing and immediate evaluation throughout radiation therapy. This distinctive feature reinforces the market advancement of image-guided radiation therapy, augmenting its utility and attractiveness within the medical domain.

The breast cancer application segment accounted for a significant share of the image-guided radiation therapy market in 2022-2028.

Based on the application, the image-guided radiation therapy market is segmented into breast cancer, prostate cancer, head & neck cancer, lung cancer, gastrointestinal cancer, gynaecological cancer, and other applications. The rising incidence of cancer worldwide is a significant driver for the image-guided radiation therapy market. The precision inherent in image-guided radiation therapy (IGRT) mitigates the necessity for frequent and discomforting repositioning of patients during treatment sessions. This is attributed to an enhanced level of patient comfort, particularly pertinent for individuals undergoing breast cancer treatment. This augmentation distinctly contributes to the advancement and attractiveness of the image-guided radiation therapy market.

IGRT enables precise tumor localization, enabling dynamic adjustments during treatment to ensure accurate radiation delivery to the tumor site. This adeptness minimizes the risk of impacting neighbouring healthy tissues unfavourably. As a result, this capability significantly contributes to the amplification of the market prominence of image-guided radiation therapy, fortifying its appeal and value proposition.

Intensity modulation radiation therapy procedure segment accounted for the largest share of the image-guided radiation therapy market in 2022-2028.

Based on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, stereotactic therapy, proton beam therapy, intensity modulation radiation therapy, and particle therapy. The intensity modulation radiation therapy procedure segment is estimated to hold the 39.2% market share of the image-guided radiation therapy market in 2022. Intensity Modulated Radiation Therapy (IMRT) is instrumental in crafting tailored treatment blueprints through the optimization of radiation administration based on tumor dimensions, contours, and placement. This congruence aligns seamlessly with the personalized treatment ethos central to Image-Guided Radiation Therapy (IGRT). The heightened precision characteristic of IMRT translates to diminished radiation exposure to vital organs and unaffected tissues, thereby attenuating the potential for treatment-induced complications. This correlation distinctly resonates with IGRT's mission to curtail adverse effects, collectively accentuating its market viability and relevance.

Hospitals segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.

The major end users in the image-guided radiation therapy market are independent radiotherapy centers and hospitals. Hospitals are expected to account for a major market share in 2022. Healthcare institutions grapple with a considerable influx of cancer patients, thereby magnifying the attraction towards image-guided radiation therapy (IGRT). The precision inherent in IGRT's tumor-targeting proficiency and its streamlined treatment delivery harmonize seamlessly with the necessity of proficiently managing the patient caseload. This symbiotic convergence not only optimizes patient-centric care but also elevates the market appeal of image-guided radiation therapy, establishing it as a pivotal therapeutic modality for healthcare establishments addressing the complexities of cancer treatment management.

Overall, Within the sphere of image-guided radiation therapy (IGRT), the hospital's end-user segment strategically capitalizes on its comprehensive healthcare provisions, state-of-the-art infrastructure, synergistic collaborative milieu, and unwavering commitment to patient-centered care to propel adoption. The cumulative impact of these facets distinctly fosters the expansion and heightened prominence of IGRT's presence within the hospital ecosystem, consequently amplifying its market position and traction.

North America to account for a significant market share in the image-guided radiation therapy market in 2022.

In 2022, the North American region is expected to register significant growth in the market during the forecast period. North America comprises the US and Canada. North America has an advanced healthcare infrastructure, which is associated with a higher incidence of cancer. In North America, a highly developed healthcare infrastructure coupled with ready access to state-of-the-art medical technologies creates a conducive environment for the assimilation of progressive treatment modalities, such as image-guided radiation therapy (IGRT). The region's notably comprehensive healthcare reimbursement frameworks further reinforce the adoption of sophisticated treatments, including IGRT, ensuring its accessibility to a broader spectrum of patients. This confluence of factors substantiates the impetus for the expansion and fortification of the image-guided radiation therapy market.

These factors collectively contribute to North America's good market share in the image-guided radiation therapy market, making it a prominent region for the adoption, manufacturing, and research of image-guided radiation therapy.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171554723

Image-Guided Radiation Therapy Market Dynamics:

Drivers:

Increase in non-invasive cancer treatments through radiation therapy
Increasing government initiatives for cancer management
Rising cancer patient population

Restraints:

The dearth of skilled radiologist/oncologist
Affordability and accessibility of treatment
Complexity of imaging technology for treatments

Opportunities:

Rising healthcare expenditure across developing countries
Expansion of key
players in emerging countries

Challenge:

Availability of alternative technology

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=171554723

Recent Developments:

- In 2023, Philips extended the company's mobile C-arm portfolio with Zenition 10.

- In 2023, GE HealthCare Advances PET/MR Capabilities with AIR Technologies to enhance diagnostic precision and simplify treatment evaluation while elevating patient comfort.

- In 2023, The launch of Pixxoscan expands GE HealthCare's portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers - Clariscan (gadoteric acid) and Pixxoscan (gadobutrol).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com